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Abstract: E-26 transformation-specific (ETS) proteins are transcription factors directing gene expression
through their conserved DNA binding domain. They are implicated as truncated forms or interchromo-
somal rearrangements in a variety of tumors including Ewing sarcoma, a pediatric tumor of the bone.
Tumor cells express the chimeric oncoprotein EWS-FLI1 from a specific t(22;11)(q24;12) translocation.
EWS-FLI1 harbors a strong transactivation domain from EWSR1 and the DNA-binding ETS domain of
FLI1 in the C-terminal part of the protein. Although Ewing cells are crucially dependent on continuous
expression of EWS-FLI1, its regulation of turnover has not been characterized in detail. Here, we identify
the EWS-FLI1 protein as a substrate of the ubiquitin-proteasome system with a characteristic polyubiq-
uitination pattern. Using a global protein stability approach, we determined the half-life of EWS-FLI1
to lie between 2 and 4 h, whereas full-length EWSR1 and FLI1 were more stable. By mass spectrome-
try, we identified two ubiquitin acceptor lysine residues of which only mutation of Lys-380 in the ETS
domain of the FLI1 part abolished EWS-FLI1 ubiquitination and stabilized the protein posttranslation-
ally. Expression of this highly stable mutant protein in Ewing cells while simultaneously depleting the
endogenous wild type protein differentially modulates two subgroups of target genes to be either EWS-
FLI1 protein-dependent or turnover-dependent. The majority of target genes are in an unaltered state
and cannot be further activated. Our study provides novel insights into EWS-FLI1 turnover, a critical
pathway in Ewing sarcoma pathogenesis, and lays new ground to develop novel therapeutic strategies in
Ewing sarcoma.
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E-26 transformation specific (ETS) 
proteins are transcription factors directing gene 
expression through their conserved DNA-binding 
domain. They are implicated as truncated forms or 
interchromosomal rearrangements in a variety of 
tumors including Ewing sarcoma, a pediatric 
tumor of the bone. Tumor cells express the 
chimeric oncoprotein EWS-FLI1 from a specific 
t(22;11)(q24;12) translocation. EWS-FLI1 harbors 
a strong transactivation domain from EWSR1 and 
the DNA-binding ETS domain of FLI1 in the C-
terminal part of the protein. Even though Ewing 
cells are crucially dependent on continuous 
expression of EWS-FLI1, its regulation of 
turnover has not been characterized in detail.  
Here, we identify the EWS-FLI1 protein 
as a substrate of the ubiquitin proteasome system 
with a characteristic poly-ubiquitination pattern. 
Using a Global Protein Stability approach, we 
determined the half life of EWS-FLI1 to lie 
between 2h-4h whereas full length EWSR1 and 
FLI1 were more stable. By mass spectrometry, we 
identified two ubiquitin acceptor lysine residues of 
which only mutation of K380 in the ETS domain 
of the FLI1 part abolished EWS-FLI1 
ubiquitination and stabilized the protein 
posttranslationally. Expression of this highly stable 
mutant protein in Ewing cells, while 
simultaneously depleting the endogenous wild 
type protein, differentially modulates two 
subgroups of target genes to be either EWS-FLI1 
protein dependent or turnover dependent. The 
majority of target genes is in an unaltered state and 
cannot be further activated.  
Our study provides novel insights into 
EWS-FLI1 turnover, a critical pathway in Ewing 
sarcoma pathogenesis and lies new grounds to 





E-26 transforming specific (ETS) family 
members are strong activators or repressors of 
transcription with a highly conserved ETS domain 
(1-3). ETS transcription factors (TFs) bind most 
commonly in complexes to a GGA core region in 
order to mediate gene expression (4,5). Their main 
biological functions include regulation of 
differentiation, lineage determination of the 
hematopoietic system and control of angiogenesis 
(6,7). Most of the ETS family members have 
oncogenic potential, since truncated or 
overexpressed ETS proteins have been linked to 
several cancer entities (8-11). ERG or ETV1 are 
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frequently fused to the TMPRSS2 promoter in 
prostate cancer, whereas ETV1 and ETV6 are 
implicated in leukemia (12,13). Like other aberrant 
fusion proteins, they act as drivers of uncontrolled 
cell growth and survival (14,15). However, most 
TFs do not harbor an enzymatic pocket and are 
therefore difficult to target directly. Novel 
strategies which uncover vulnerable sites in TFs 
are urgently needed to develop novel targeted 
therapies (16).  
Ewing sarcoma is a rare pediatric bone and 
soft tissue tumor with an aggressive behavior and 
prevalence to metastasize (17,18). Its main genetic 
abnormalities are EWS–ETS rearrangements, 
among them most commonly the EWS gene on 
chromosome 22 fused to FLI1 on chromosome 11 
which results in expression of the chimeric 
transcription factor EWS-FLI1 (19-21). 
Continuous expression of the fusion protein is 
crucial for tumor formation, progression and 
maintenance (22,23) and its downregulation 
inhibits proliferation and reduces tumor cell 
growth (24-26). EWS-FLI1 is thought to function 
mainly as modulator to activate and repress a wide 
range of target genes, but also to regulate splicing 
processes or being a component of large 
interaction networks (27-31). However, inhibition 
of a single downstream target gene has not been 
proven effective yet for Ewing sarcoma therapy.  
The turnover of most intracellular proteins 
is mediated via the ubiquitin proteasome system 
(UPS) which triggers protein degradation (32). 
Several ETS proteins can be poly-ubiquitinated by 
different E3 ligases and subsequently degraded by 
the proteasome (33-36). Considering their high 
conservation, proteasomal degradation is likely to 
be the main mechanism of turnover for most ETS 
family members. Most interestingly, truncated 
ERG and ETV1 are lacking the N-terminal E3 
binding domain which results in a delayed 
turnover of aberrant ETS proteins (34, 36). Here, 
we focus specifically on the turnover of the fusion 
protein EWS-FLI1 which only harbors the ETS 
and the C-terminal domain from FLI1. The impact 
on the turnover of this domain fused to N-terminal 
region of EWSR1, has not been investigated yet. 
Hence, EWS-FLI1 proteasomal turnover 
represents a so far uncharacterized mechanism in 
Ewing sarcoma tumorigenesis, even though EWS-
FLI1 degradation has already been linked to the 
lysosomal pathway (37). Moreover, the exact 
lysine acceptor residues for poly-ubiquitination 
have not yet been identified for any wild type or 
truncated ETS protein.  
In the present study, we demonstrate that 
EWS-FLI1 is predominantly a proteasomal 
substrate with an unexpectedly high turnover rate 
mediated by poly-ubiquitination at a single lysine 
residue. Surprisingly, expression of this highly 
stable mutant protein in Ewing cells specifically 
induced subgroups of high-level expressed or 
turnover sensitive target genes, while the majority 
of target genes are unaltered.  
Hence, our study provides novel insights 
into EWS-FLI1 turnover suggesting that deflecting 
its stability could contribute to new therapeutic 




EWS-FLI1 turnover is proteasome 
dependent. Since EWS-FLI1 expression is crucial 
for tumor cell survival (24-26), we were interested 
to analyze degradation and turnover rate of the 
fusion protein. To address this, we first used a 
panel of six different inhibitors targeting 
proteasomal, lysosomal and autophagosomal 
protein degradation pathways. Incubation with 
20µM of the various inhibitors resulted in a 2-fold 
upregulation of EWS-FLI1 protein levels only 
upon MG-132 and Bortezomib treatment, both 
inhibitors of the chymotrypsin-like proteasome 
activity (Fig. 1A). We next confirmed this result 
by selectively inhibiting the proteasomal and 
lysosomal degradation pathways with two 
compounds in three different Ewing sarcoma cell 
lines. Incubation with 20µM of the proteasome 
inhibitor MG-132 resulted in stabilization of 
endogenous EWS-FLI1 fusion protein by at least 
2-fold while this was not the case for the 
lysosomal inhibitor chloroquine (Fig. 1B). P27 and 
LAMP1 were used as positive controls and 
showed upregulation after treatment as expected. 
In addition, stabilization of the fusion protein in 
Ewing cells by MG-132 increased over a 2h-8h 
treatment period in a time- dependent manner (Fig. 
1C). Hence, degradation of EWS-FLI1 is primarily 
proteasome dependent under steady-state 
conditions. However, incubation with 20µM 
cycloheximide (CHX) had only limited reducing 
effect on the endogenous fusion protein in the 
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Next, we investigated whether the fusion 
protein is ubiquitinated. To this end, 3xflag-EWS-
FLI1 was co-expressed with HA-ubiquitin in 
HEK293T cells and immunoprecipitated after 48h 
using anti-flag antibody. Western blotting with an 
anti-HA antibody revealed at least four distinct 
ubiquitin bands for EWS-FLI1 which could not be 
increased by prior treatment with MG132 (Fig. 
1E), suggesting a constant ubiquitination of the 
fusion protein. We next co-expressed 3xflag-EWS-
FLI1 with wild type HA-ubiquitin or ubiquitin 
mutants which are deficient for K48- and K63- 
linked chains. Immunoprecipitation of the 
ubiquitinated 3xflag-EWS-FLI1 revealed mainly a 
decrease of the ubiquitination pattern using K48R 
HA-ubiquitin (Fig. 1F) indicating that this is the 
major, but not only, linked ubiquitin chains of the 
fusion protein 
To further validate the fusion protein 
turnover and to overcome the limitations of 
classical CHX treatment to determine protein half 
lives, we next used the Global Protein Stability 
(GPS) approach (38) (Fig. 2A). Briefly, HEK293T 
cells were transduced with a reporter construct 
DsRed-IRES-EGFP in which EGFP is fused to 
EWS-FLI1. The ratio EGFP/DsRed was 
determined by FACS and represents a measure for 
protein stability. Known degron motifs with 
distinct half lives were used as internal standards 
and allowed to estimate the half life of EWS-FLI1 
to be between 1h and 4h (Fig. 2B). Incubation with 
MG-132 shifted the ratio closer to 4h, confirming 
that EWS-FLI1 is a substrate of the proteasome 
system with a high turnover rate. Additionally, we 
treated cells with the nuclear export inhibitor 
leptomycin B (LMB) for 4h and 8h. Treatment 
with 50nM LMB stabilized EWS-FLI1 in a time-
dependent manner (Fig. 2C) indicating that the 
proteasomal degradation mainly occurs in the 
cytosol. Similar results were obtained in 
transiently or stably transduced Ewing cells (Fig. 
2D-E), suggesting that the high turnover of EWS-
FLI1 is mostly independent of the cellular 
background. Interestingly, incubation with 20µM 
CHX again displayed a limited effect on the 
EGFP/DsRed ratio of EWS-FLI1 reporter 
construct (Fig. 2B,2E) indicating that classical 
CHX barely reflects the steady- state turnover rate 
of the EWS-FLI1 protein and possibly other 
proteins. 
Taken together, our results indicate that 
EWS-FLI1 is a poly-ubiquitinated protein with an 
unexpectedly high turnover rate in Ewing sarcoma 
cells. 
 
 EWS-FLI1 turnover depends on one 
critical lysine residue. To better understand 
fusion protein turnover, we aimed to identify the 
lysine residue(s) that are important for 
degradation. To this, we purified large amounts of 
3xflag-EWS-FLI1 or a dominant-negative R386N 
mutant (39,40) from HEK293T cells. The inactive 
mutant was included as the inability to bind DNA 
increases the possibility for ubiquitination. Both 
samples were then enzymatically digested and 
subjected to mass spectrometry to identify peptide 
shifts due to covalently attached ubiquitin. This 
identified two peptides with the characteristic 
glycine-glycine shift including residues K298 and 
K380 (Fig. 3A, supplementary S1A). To determine 
whether both sites are important for fusion protein 
turnover, we mutated them individually to 
arginine. After co-expressing the mutant EWS-
FLI1 with HA-ubiquitin and immunoprecipitation 
from A673 Ewing cells, we found that the K298R 
mutant was still ubiquitinated comparable to the 
wild type, while the K380R lost this characteristic 
pattern (Fig. 3B). In addition, transient expression 
of the mutants in both A673 and SKNMC Ewing 
cells revealed that the K380R and the double 
mutant K298/380R were 2.5-fold, 3.5-fold 
respectively, more stable than wild type or the 
K298R mutant (Fig. 3C-D). As wild type EWS-
FLI1, also the K380 mutant was still localized in 
the nucleus (Fig. 3E). We then investigated the 
role of both lysines in proteasomal turnover by 
GPS. The half life of the K298R was comparable 
to wild type EWS-FLI, while K380R shifted close 
to 24h (Fig. 3F). Wild type EWS-FLI1 and the 
K298R could be stabilized by an additional 
incubation with MG-132, however the 
EGFP/DsRed ratio of the K380R mutant did not 
change upon treatment (Fig. 3G). Hence, our 
findings suggest that K380 is the major site 
required to regulate EWS-FLI1 protein turnover by 
the proteasome. 
 
EWS-FLI1 fusion protein and wild type 
FLI1 share a unique site for turnover. To 
investigate whether turnover by K380 is unique to 
the fusion protein, we subsequently compared 
stability and ubiquitination pattern to the full 
length proteins EWSR1 and FLI1. Surprisingly, 
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lives of >4h (FLI1) and close to 24h (EWSR1) 
(Fig. 4A). While FLI1 could be stabilized by 
incubation with MG-132 (or destabilized by 
CHX), EWSR1 did not change its already long 
half life by these treatments (Fig. 4B). As FLI1 
was clearly poly-ubiquitinated similar to the fusion 
protein, EWSR1 showed strong mono- and di-
ubiquitination (Fig 4C). Next, we mutated the 
previously identified lysine residue to arginine 
(FLI1: K334). By GPS, the K334R also increased 
its half life towards 24h (Fig. 4D). Additionally, 
mass spectrometry of purified 3xflag-FLI1 
revealed glycine-glycine shifts for peptides 
containing lysines K172 and K252 (peptide spectra 
in supplementary S1B-C). Whereas K172 is 
located in the N-terminal part and therefore not 
present in the fusion protein, K252 corresponds to 
the EWS-FLI1 K298 residue. Single arginine 
mutants of both residues display EGFP/DsRed 
ratios comparable to wild type FLI1 (Fig. 4D, 
dotted lines) indicating that both fusion and full 
length protein turnover is regulated by one single 
lysine residue. Indeed, incubation of FLI1 and 
K334R with MG-132 only shifted the wild type, 
but not the K334R mutant ratio (data not shown). 
Interestingly, the K334/K380 residue is conserved 
within most ETS family members (Fig. 4E). 
Together, our findings indicate that, 
despite differences in turnover, stability of both 
EWS-FLI1 and wild type FLI1 is regulated by the 
same critical conserved residue in the ETS 
domain. 
 
EWS-FLI1 target genes expression is 
subdivided into three major groups. Modulation 
of EWS-FLI1 target gene signature is one of the 
best studied mechanisms in Ewing sarcoma. EWS-
FLI1 is activating a wide range of target genes like 
NKX2.2, NR0B1 or IGF1 (30,31,41-43), but has 
also repressive functions as shown for IGFBP3, 
PHLDA1 and LOX (44-46). Consequently, this is 
thought to be critical for oncogenic properties as 
depletion of the fusion protein results in growth 
inhibition and cellular senescence (24,47). To 
better understand the effect of EWS-FLI1 stability 
on the target gene signature, we established 
inducible exchange cell lines which were capable 
to knock down the endogenous EWS-FLI1 while 
simultaneously expressing 3xflag-EWS-FLI1 or 
the K380R mutant. To this, we first sorted cells 
expressing these flag tagged overexpression 
constructs by flow cytometry for the same low 
EGFP expression (the selection marker of the 
pInducer21 vector) to obtain a homogeneously 
expressing population (Fig. 5A). We then 
subsequently transduced each of these clonal pools 
with two different shRNA constructs against the 
3’UTR of EWS-FLI1 (Fig. 5B). Upon doxycyline 
induction for 48h, endogenous EWS-FLI1 was 
exchanged with ectopic wild type or mutant 
3xflag-EWS-FLI1versions (Fig. 5C). As observed 
before, the K380R mutant stabilized the protein 
posttranslationally by at least four-fold (Fig. 5C) 
while EWS-FLI1 mRNA levels were comparable 
as shown for shEF#2 (Fig. 5D, not shown for 
shEF#1 based cell lines). We then extracted total 
RNA for microarray expression profiling and 
analyzed the EWS-FLI1 target genes signature for 
their differential expression upon stabilized fusion 
protein (supplementary S2). A total of 497 probe 
sets were downregulated by at least 1.5-fold due to 
EWS-FLI1 depletion from which 250 could be 
rescued to at least normal levels by induction of 
EWS-FLI1 wild type (Fig. 6A-B). Only if the 
EWS-FLI1 target genes were modulated and 
recovered in the paired comparison of EWS-FLI1 
induction and knockdown at each 24h and 48h, 
they were considered as rescued. This pattern was 
similar for repressed target genes as 333 probe sets 
were at least 1.5-fold upregulated from which 164 
could be again repressed by ectopic EWS-FLI1 
(Fig. 6A, 6C). However, we were most interested 
in the target genes which were further modulated 
with stabilized protein levels. Surprisingly, the 
large majority of these genes appeared to be 
unmodified and displayed no difference in target 
gene expression between wild type and mutant 
EWS-FLI1. However, two subgroups were 
modulated differentially by the mutated fusion 
protein. One subgroup seems to be protein 
sensitive as 15 individual genes displayed higher 
RNA levels by at least 1.5-fold upon expression of 
stabilized EWS-FLI1 protein. From the other 
subgroup, 29 rescued candidates were fusion 
protein turnover sensitive and could only partly be 
modulated by the mutant in comparison to wild 
type EWS-FLI1 (Fig. 6A-B, list supplementary 
S2). Among the protein sensitive candidates, IGF1 
and long non-coding RNA EWSAT1 have been 
already characterized (41,48) while most other 
target genes have not been implicated in EWS-
FLI1 oncogenesis. Selected target genes from the 
protein dependent and unmodified group were 













EWS-FLI1 degradation is mediated by one lysine residue 
5 
different shEWS-FLI1 sequences (Fig. 6D, shown 
for shEF#2). Even though the exact mechanism of 
EWS-FLI1 gene repression is not fully understood, 
the pattern of target gene modulation resembled 
that of activated target genes. The majority of 
repressed genes were unmodified, but also here 
two subgroups differentially modulated repression 
upon expression of stabilized protein levels (Fig. 
6C, 6E, list supplementary S2). 
Taken together, our results indicate that 
82% of activated, and 93% of repressed target 
genes have unaltered levels and cannot be further 
increased by higher EWS-FLI1 protein levels. 
Only subsets of the target gene signature are 
differentially modulated implying that stability of 
EWS-FLI1 directs these important subgroup or 




Here, we demonstrated that EWS-FLI1 is 
a polyubiquitinated substrate that is primarily 
degraded by the proteasome. The high turnover of 
the fusion protein is controlled by one critical 
lysine residue located in the conserved ETS 
domain. By exchanging the wild type EWS-FLI1 
with its turnover deficient mutant, we could show 
that protein stabilization differentially modulates 
two subsets of target genes whose expression 
could either be enhanced (protein dependent) or 
only partially rescued (turnover dependent). 
However, the majority of target genes are in an 
unmodified state and independent of protein 
stabilization. 
Attachment of ubiquitins to a substrate 
triggers a variety of outcomes including 
degradation and signaling depending on the 
ubiquitin acceptor site and ubiquitin chain linkage 
(32). Here, we identified the fusion protein EWS-
FLI1 as a substrate of the proteasome system in a 
time and dose dependent manner. The previously 
suggested lysosomal degradation route (37) 
possibly contributes to turnover, but appears less 
relevant compared to the proteasomal pathway 
under steady state conditions.  
During the last decades, a variety of different 
technologies have been developed to dissect and 
understand ubiquitin mediated processes (49). GPS 
profiling was initially established to identify novel 
proteasomal or cullin-RING ligase substrates 
(38,50,51). Thus, we applied this approach to 
analyze EWS-FLI1 turnover. Displaying the 
EGFP/DsRed ratio for the fusion protein and 
known standard reporter constructs, we confirmed 
EWS-FLI1 turnover as proteasome dependent and 
mapped the half life to be between 1h-4h. As most 
potent transcription factors, also EWS-FLI1 
displays a fast turnover (52,53). Using Leptomycin 
B, we could show that EWS-FLI1 is indeed 
exported out of the nucleus for degradation 
suggesting that the fusion protein tightly keeps 
balance of its cytosolic proteolysis. The apparent 
exclusive nuclear localization might therefore be 
due to its rapid cytosolic degradation. 
However, incubation of cells with the 
translation synthesis inhibitor CHX barely 
reflected the high turnover observed in the GPS 
under steady-state conditions. Using this assay, 
others already suggested EWS-FLI1 as a stable 
protein (37). In contrast, by using antisense 
oligodeoxynucleotides (26) and RNAi approaches, 
it is known that the fusion protein can be 
efficiently downregulated within a short 24h time 
frame which would not be possible with a highly 
stable protein. The discrepancy between the 
GPS/RNAi data and CHX treatment therefore 
remains. However, complete inhibition of protein 
synthesis by CHX also affects other components 
of the ubiquitin system such as E2 conjugating 
enzymes or E3 ligases. Possibly, if a required E3 
ligase is unstable and immediately depleted, EWS-
FLI1 turnover might be prolonged as seen here 
with classical CHX treatment. 
While EWS-FLI1 has been shown to be 
posttranslationally modified (54-56), 
ubiquitination remained unknown. Here, we 
demonstrated that the fusion protein is 
polyubiquitinated with a clear and distinct pattern 
which supports the concept of a constant turnover. 
To better understand how the ubiquitinated fusion 
protein is degraded, we used affinity purified 
EWS-FLI1 for mass spectrometry and searched for 
glycine-glycine modifications in the fragmented 
peptide sequence. From two possible ubiquitin 
acceptor sites, only mutation of the K380 clearly 
abolished ubiquitination and posttranslationally 
stabilized the protein. While focusing on EWS-
FLI1 degradation, we do not exclude that this 
critical lysine may also trigger non-proteolytic 
signaling via alternative linked polyubiquitin 
chains. It is also worth to mention here that we 
have analyzed our mass spectrometry data for 
occurrence of glycine-glycine shifts of the 
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shifts mainly for K48-, but also K63-linked 
ubiquitins (data not shown) confirming our 
findings that K48-linked chains are highly 
abundant, but not the exclusive EWS-FLI1 
ubiquitination pattern. Other ubiquitin linked 
chains or mixed chains might also be relevant. 
Further, mutation of this residue may also 
inhibit other modifications such as sumoylation. 
Acetylation of this residue has not been detected in 
contrast to the K298 site (55).  
 
The comparison of EWS-FLI1 with its full 
length proteins revealed that the polyubiquitin 
pattern is similar to FLI1. Indeed, mutation of the 
corresponding lysine residue in the ETS domain 
posttranslationally stabilizes both proteins. As the 
K380/K334 residue is highly conserved among 
most ETS family members, it might contribute to 
proteasomal degradation in other ETS proteins and 
their fusion proteins. Most interestingly, EWS-
FLI1 displays a higher turnover compared to its 
full length proteins EWSR1 and FLI1. In contrast, 
the ETS proteins ERG or ETV1 which are fused to 
the TMPRSS2 promoter in prostate cancer 
stabilize the protein and confer a physiological 
advantage to cancer cells (33,34,36). The truncated 
protein versions display increased stability due to 
loss of the N-terminal E3 ligase motif. However, 
EWS-FLI1 is not a truncated version of FLI1, 
instead the N-terminal domain is dominated by 
EWSR1 with a stronger transactivation domain. If 
the turnover and subsequent E3 ligase binding of 
ETS members is conserved, EWS-FLI1 might 
possibly interact with E3 ligases via its EWSR1 
domain giving rise to a new regulatory 
mechanism. However, the basic concept that 
truncated oncogenic TFs are more stable than their 
wild type counterparts (36) might not apply for 
fusion proteins consisting of two unrelated protein 
domains. Whether this is indeed a general 
paradigm or rather specific for EWSR1 related 
fusion proteins needs to be further elucidated.  
We then deciphered the role of EWS-FLI1 
turnover in transcriptional regulation of target 
genes. To investigate the influence of stabilized 
EWS-FLI1 on target gene expression, we 
established an inducible Ewing cell system 
allowing to deplete endogenous EWS-FLI1 protein 
while simultaneously expressing the wild type 
fusion protein or a turnover deficient mutant. This 
system largely circumvents interference with 
endogenous fusion protein, enabling us to study 
the dynamic behavior of posttranslationally 
stabilized EWS-FLI1 protein on transcriptional 
regulation. Surprisingly, around 85% of both 
activated and repressed target genes are in an 
unaltered state including well characterized target 
genes such as NR0B1 or STEAP1 (30,57).  
Even though our EWS-FLI1 wild type 
overexpression constructs are around 2-fold above 
the endogenous EWS-FLI1 levels, it is possible 
that co-factors expressed at endogenous levels or 
interacting proteins are limiting further 
modulation. The knowledge of the EWS-FLI1 
interactome is continuously expanding (28,29), 
however, it still remains unsolved which co-factors 
or interacting proteins are most important or 
influence the fusion protein in a context dependent 
matter. Nevertheless, longer induction of wild type 
or mutated ectopic EWS-FLI1 up to 96h induced 
cell death irrespective of the construct (data not 
shown).  
Besides the majority of unmodified target 
genes, two other subgroups display a different 
behavior. 15 activated target genes are higher 
expressed upon stabilized EWS-FLI1 protein 
levels. This group includes protein-coding genes 
such as IGF1 (41) or LEMD1 and RNA-coding 
genes such as EWSAT1 (48). Interestingly, 
EWSAT1 was also observed to be elevated upon 
higher EWS-FLI1 expression in a different 
experimental setting (48) suggesting that our 
approach reflects a global pattern. Further, 29 
activated target genes are less expressed upon 
stabilized EWS-FLI1. None of these turnover 
sensitive target genes have yet been characterized 
even though few interesting candidates as ALK or 
TP63 appeared.  
Most interestingly, the activity of TFs can 
be influenced by their own turnover as shown for 
estrogen receptor α or c-MYC (58,59). It was 
recently shown that the proteasomal turnover of c-
myc is required for full activity. Lysine mutated c-
MYC failed to induce tumorigenesis as inhibitory 
complexes could not be removed during target 
gene activation (58) while other TFs are 
independent of ongoing degradation for their 
transcriptional activity (60). Surprisingly, EWS-
FLI1 induced distinct behavior in three subgroups 
of target genes. Speculatively, the two small 
subgroups of EWS-FLI1 protein sensitive and 
turnover sensitive target genes might be of greater 
importance and their dynamics might trigger 
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oncogenicity. Even though it is not yet clear how 
these subgroups are defined at their regulatory 
regions, possible driver target genes might be 
found in these two subgroups. Alternatively, since 
we see most target gene levels unaltered, 
oncogenic properties might depend also on 
additional mechanisms such as interacting proteins 
and/or influence on the splicing machinery. 
 
Taken together, turnover regulation of the 
major oncogenic driver EWS-FLI1 represents an 
important regulatory mechanism in Ewing 
sarcoma pathogenesis. Interference with fusion 
protein degradation might not only be a novel 
therapeutic strategy in Ewing sarcoma treatment, 
but might also be applicable to other ETS based 




Cell lines and reagents- HEK293T cells 
were cultured in DMEM (Sigma Aldrich, Buchs, 
Switzerland) supplemented with 10% FBS (Sigma 
Aldrich), 2mmol/L glutamine (BioConcept, 
Allschwil, Switzerland) and 100U/ml 
penicillin/streptomycin (ThermoFisher Scientific 
AG, Reinach, Switzerland) at 37°C in 5% CO2. 
Ewing sarcoma cell lines A673, SKNMC and 
TC71 were cultured in RPMI as described above. 
Additionally, dishes were pre-coated with 0.2% 
gelatine (Sigma Aldrich). All cell lines have been 
tested mycoplasma negative. The following 
reagents were used: Bortezomib (Selleckchem, 
Houston, TX, USA), Chloroquine, cycloheximide, 
DMSO, doxycycline, E64, leptomycin B (all 
Sigma Aldrich), LY294002, MG-132 (Millipore, 
Billerica, MA, USA) and 3-Methyladenine 
(ApexBio, Houston, TX, USA). 
 
Plasmids and cloning- The coding 
sequence for human EWS-FLI1, FLI1 and EWS, 
were subcloned into the Not1 site of pCMV-3xflag 
vector (Sigma Aldrich). For Global Protein 
Stability, the coding sequences of DsRed-IRES-
EGFP or d24-EGFP or d4-EGFP or d1-EGFP 
(addgene #41941, #41944, #41943, #41942) were 
cloned into the EcoR1 site of pR-EF1 (Cellecta 
Inc., Mountain View, CA, USA). All cDNAs 
(EWS-FLI1, FLI1, EWS and mutants) were 
inserted into the BSTB1 site at the 3’ end of 
DsRed-IRES-EGFP. 
3xflag-EWS-FLI1 cDNA was cloned into the 
Spe1-BamH1 sites of pInducer21 ORF (Addgene 
#46948). The pRSIT-U6Tet-shRNA-PGKTetRep-
2A-GFP-2A-puro vector with shRNAs against 
EWS-FLI1 was purchased from Cellecta Inc. with 
the following target sequences: shEF#1 5’ 
ATAGAGGTGGGAAGCTTATAA 3’ (previously 
described in (31)) and shEF#2 5’ 
CGTCATGTTCTGGTTTGAGAT 3’ (designed 
against the C-terminal FLI1 part according to 
RefSeq# NM_002017.4). 
Cloning was performed by In-Fusion cloning HD 
(Clontech Laboratories Inc., Mountain View, CA, 
USA) according to manufacturer’s protocol. All 
mutations were introduced using site-directed 
mutagenesis. Detailed information of plasmids, 
cloning and mutagenesis primers can be found in 
supplementary table ST1. All clonings were 
verified by sequencing. 
 
Transient transfection- For HEK293T 
cells, DMEM complete medium was mixed with 
PolyethylenimineMax (Polyscience, Cham, 
Switzerland) and plasmids for 15min and added to 
the cells for 48h. For Ewing sarcoma cells, 
JetPrime (Polyplus Transfections, Illkirch, France) 
reagent was used according to manufacturer’s 
instruction in antibiotics-free RPMI medium.  
 
Viral production and transduction- 
HEK293T cells were transfected with cDNA 
vectors and pMDL, pREV, and pVSV with 
JetPrime according to manufacturer’s instruction 
in antibiotics-free DMEM medium. Medium was 
replaced 24h after transfection and virus was 
harvested after additional 48h. Viral supernatant 
was cleared by centrifugation, filtered and 
concentrated if necessary (Amicon® Ultra 15 mL, 
Millipore). Ewing sarcoma cells were infected 
with the viral supernatant supplemented with 
10µg/ml polybrene (Sigma Aldrich) for 16-18h. 
 
Global Protein Stability Assay and flow 
cytometry- Lentivirus from HEK293T transfected 
with pR-EF1-DsRed-IRES-d1/d4/d24/EGFP-
cDNA, pMDL, pREV and pVSV was used to 
transduce HEK293T or Ewing sarcoma cells as 
described to about 5-10% of DsRed positive cells. 
Cells were harvested 72h after transduction, 
incubated with cycloheximide, leptomycin B or 
MG-132 for 4-8h as indicated and analyzed by 
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using a 40μm cell strainer (BD Becton, Dickinson 
and Company, Franklin Lakes, NJ, USA). FACS 
analysis was performed on a FACS CantoTM II 
Cytometry system (BD) and data were analyzed by 
FlowJo software (Treestar Inc., Ashland, OR, 
USA). At least 50000 cells were recorded for each 
experiment. Cell sorting was done with a FACS 
AriaTM III Cytometry system (BD).  
 
Cell lysis, western blotting and 
antibodies- Cells were harvested and lysed in 
standard lysis buffer (50mM Tris/HCl, 150mM 
NaCl, 50mM NaF, 5mM Na4P2O7, 1mM Na3VO4 
and 10mM ß-glycerolphosphate, 1% TritonX with 
protease inhibitor cocktail, Complete Mini® 
(Sigma Aldrich)). Lysates were sonicated and 
cleared by centrifugation. Proteins were separated 
by 4%-12% or 10% BisTris NuPAGE pre-cast gels 
(ThermoFisher Scientific AG) and transferred to 
nitrocellulose membranes (GE Healthcare). 
Membranes were blocked with 5% milk powder in 
0.2% PBS-Tween and primary antibodies were 
incubated over night at 4°C followed by 2h of 
HRP-linked secondary antibody at room 
temperature. Proteins were detected by 
chemiluminescence using Amersham ECL 
detection reagent (GE Healthcare, Glattbrugg, 
Switzerland) or SuperSignalTM Western blotting 
reagent (ThermoFisher Scientific AG). 
Quantification of blots was performed by using 
ImageJ (version 1.46r). The following commercial 
antibodies were used: anti-Actin (dilution 1:1000, 
Cell Signaling), anti-Flag (clone M2, 1:1000, 
Sigma Aldrich), anti-FLI1 (1:1000, MyBiosource 
LLC, San Diego, CA, USA), anti-GAPDH 
(1:1000, Cell Signaling), anti-HA (1:1000, 
Millipore), anti-LAMP1 (1:500, DSHB, Iowa City, 
Iowa, USA), anti-p27 (1:1000, Cell Signaling and 
1:200 ThermoFisher Scientific AG) and anti-
Tubulin (1:40000 Sigma Aldrich).  
 
Immunoprecipitation of ubiquitinated 
proteins- Cells were transfected for 48h and 
treated with 10µM MG-132 prior to lysis in 
ubiquitin lysis buffer (2% SDS, 150mM NaCl, 
10mM Tris/HCl, 2mM Na3VO4, 50mM NaF with 
Complete Mini Protease inhibitor cocktail), boiled 
for 10min and sonicated. Lysates were diluted 1:10 
in dilution buffer (150mM NaCl, 10mM Tris/HCl, 
2mM EDTA, 1% Triton X), incubated for 30min 
at 4°C and cleared by centrifugation for 30min at 
maximum speed. Immunoprecipitation was 
performed using anti-Flag antibody (Sigma 
Aldrich) coupled to Dynabeads ProteinG 
(ThermoFisher Scientific AG). Lysates were 
incubated for 1h at 4°C, washed three times, eluted 
at room temperature using 3xflag peptide (Sigma 
Aldrich) and prepared for western blot analysis. 
Extended description for detection of EWS-FLI1 
ubiquitination sites by mass spectrometry can be 
found in supplementary S1. 
 
Immunofluorescence and microscopy- 
A673 cells were seeded on cover slides for 24h 
and transiently transfected with flag tagged 
plasmids for additional 48h. After fixing with 4% 
PFA (Carl Roth, Arlesheim, Switzerland), cells 
were permeabilized and stained with anti-Flag 
antibody (1:300, Sigma Aldrich) in 4% horse 
serum (Sigma Aldrich) and 0.1% PBS-TritonX 
over night. Fluorescent secondary antibody 
(Alexa-488 anti-mouse, Sigma Aldrich) in PBS 
with 4% horse serum was applied for 1h. Cover 
slides were fixed on objective glass with DAPI 
Vectashield® mounting medium (Vector 
laboratories Inc., Burlingame, CA, USA) and 
analyzed by an Axioskop 2 MOT Plus (Carl Zeiss 
Microscopy LLC, Thornwood, NY, USA). 
 
Quantitative PCR and microarray 
analysis- Total RNA was extracted from Ewing 
sarcoma cells using Qiagen RNeasy Kit (Qiagen 
Instruments AG, Hombrechtikon, Switzerland). 
cDNA synthesis was carried out using High-
Capacity Reverse Transcription Kit (Applied 
Biosystems by ThermoFisher Scientific AG). 
Quantitative PCR was performed using TaqMan 
gene expression master mix (ThermoFisher 
Scientific AG) and assays on demand (Applied 
Biosystems by ThermoFisher Scientific AG). A 
complete list can be found in supplementary table 
ST1. Replicate values were pooled and represented 
as geometric mean values with a 95% confidence 
interval. Microarray expression analysis with total 
RNA was performed using GeneChip® Human 
Gene 2.0 ST Array (Atlas Biolabs, Berlin, 
Germany). Data are accessible under GSE81018.  
 
Microarray data analysis- The raw 
microarray data were processed and normalized 
using the RMA algorithm (61). Differential 
expression was computed using the Bioconductor 
package limma providing a moderated t-test that is 
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Differential expression results were filtered based 
on fold-change and p-values. All computations 
were done using R/Bioconductor. Extended 
description for target gene grouping can be found 
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FIGURE LEGENDS 
Figure 1: EWS-FLI1 protein turnover is proteasome dependent. (A) Western blot analysis of 
EWS-FLI1 protein levels. A673 cells were treated with 20µM of indicated compounds for 8h, EWS-FLI1 
protein levels were detected with anti-FLI1 antibody. Quantification represents ratio of FLI1 over 
GAPDH compared to DMSO control. (B) EWS-FLI1 turnover in various Ewing sarcoma cell lines. A673, 
SKNMC and TC71 cells were treated with 20µM MG-132 or chloroquine (CQ) for 10h (A673), 8h 
(SKNMC) and 9h (TC71), and immunoblotted with anti-FLI1 antibody. Quantification represents ratio of 
FLI1 over tubulin compared to DMSO control. (C) EWS-FLI1 stabilizes in a time-dependent manner. 
Western blot of A673 cells treated with 10µM MG-132 for indicated time points. Three independent 
experiments were quantified and are represented in the scatter blot with n=3 (2h-8h) or n=5 (DMSO), 
error bars as SD. (D) Half-life of endogenous EWS-FLI1 protein. Western blot of A673 cells treated with 
20µg/ml CHX for indicated hours. Quantification of three independent experiments with n=3 (2h-8h) or 
n=5 (DMSO), error bars as SD. (E) EWS-FLI1 is ubiquitinated. 3xflag-EWS-FLI1 and HA-ubiquitin were 
co-expressed for 48h in HEK293T cells and incubated with 10µM MG-132 for indicated hours. After 
immunoprecipitation of EWS-FLI1 with anti-Flag, ubiquitination was visualized by anti-HA antibody. (F) 
EWS-FLI1 ubiquitination consists of K48-linked ubiquitin chains. 3xflag-EWS-FLI1 and wild-type or 
mutant HA-ubiquitins were co-expressed for 48h in HEK293T cells, immunoprecipitated and 
ubiquitination was visualized by anti-HA antibody. 
 
 
Figure 2: The EWS-FLI1 protein displays a high turnover. (A) Scheme illustrating GPS 
approach in which a reporter construct of DsRed-IRES-EGFP is fused at the C-terminus of EGFP to a 
protein of interest. The EGFP/DsRed ratio is determined by FACS and represents a measure for protein 
stability. (B) EWS-FLI1 turnover measured by GPS. HEK293T were transduced for 72h with a reporter 
construct fused to EWS-FLI1 or degron (d) motifs with half lives of 1h (d1h), 4h (d4h) and 24h (d24h) 
and analyzed by FACS. The reporter construct fused to EWS-FLI1 was additionally incubated with 20µM 
MG-132 or 20µg/ml CHX for 8h or (C) with 50nM Leptomycin B (LMB) for 4h and 8h (dotted line). (D) 
EWS-FLI1 stability in Ewing cell line A673. GPS analysis of reporter constructs fused to EWS-FLI1 or 
standard degron motifs 72h after transduction. (E) A673 cells stably transfected with reporter-EWS-FLI1 
construct were sorted and incubated with DMSO, 20µM MG-132 or 20µg/ml CHX for 8h. 
 
 
Figure 3: Mass spectrometry identifies K380 residue as the main ubiquitination site. (A) Two 
lysine residues were identified to be ubiquitinated by mass spectrometry. Peptide spectra with glycine-
glycine shift for residue K380 (peptide spectra for the K298 site in supplementary S1A). (B) Mutation of 
lysine residue K380 prevents EWS-FLI1 ubiquitination. 3xflag-EWS-FLI1, K298R and K380R mutants 
were co-expressed with HA-ubiquitin for 48h in A673 cells, purified ubiquitinated EWS-FLI1 was 
analyzed using anti-HA antibody by western blotting. (C) Mutated K380 residue stabilizes EWS-FLI1 
protein. 3xflag-EWS-FLI1, single and double mutants were transiently overexpressed for 48h in A673 and 
SKNMC cells and analyzed with an anti-Flag antibody by western blot. (D) Scatter blot for quantification 
for n=3 independent experiments, error bars as SD. (E) EWS-FLI1 mutant show nuclear localization. 
3xflag-EWS-FLI1 and K380R single mutant were transiently expressed for 48h in A673 cells. Cells were 
fixed, stained with anti-Flag antibody and used for immunofluorescence (40x magnification). (F) Mutation 
of K380 stabilizes EWS-FLI1 posttranslationally. HEK293T cells were transduced for 72h with reporter 
constructs of EWS-FLI1, mutants K298R and K380R and standards. EGFP/DsRed ratios were analyzed 
by FACS, (G) after additional incubation with DMSO or 20µM MG-132 for 8h. 
 
 
Figure 4: Regulation of proteasomal turnover is conserved between EWS-FLI1 and FLI1. 
(A) EWS-FLI1 displays fastest turnover. GPS analysis of EWS-FLI1, EWSR1 and FLI1 reporter 
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proteins EWSR1 and FLI1 were additionally treated with 20µM MG-132 or 20µg/ml CHX for 8h. (C) 
Immunoprecipitation of EWS-FLI1, EWSR1 and FLI1 proteins. 3xflag tagged versions were co-expressed 
with HA-ubiquitin for 48h and stabilized for additional 5h with 20µM MG-132. After 
immunoprecipitation of tag proteins, ubiquitin pattern was analyzed by anti-HA antibody. (D) Mutation of 
conserved residue K334R stabilizes FLI1 in GPS analysis. HEK293T cells were transduced for 72h with 
reporter constructs of FLI1, mutants K172R, K252R, K334R and standards. EGFP/DsRed ratio was 
analyzed by FACS. (E) Turnover dependent lysine residue is conserved within most ETS family members. 
ClustalW alignment of conserved ETS domain sequence, K334/K380 residue is marked in red.  
 
 
Figure 5: Generation of exchange Ewing cell lines. (A) EGFP (selection marker) sorting of 
pInducer21 vector transduced cells. A673 cells with 3xflag, 3xflag-EWS-FLI1 or 3xflag-K380R mutant 
were sorted for same low EGFP expression. After sorting, all cell pools were analyzed by FACS for EGFP 
and plotted for corresponding mean fluorescent intensity (MFI). (B) ShEF sequences shRNA against the 
3’ UTR of EWS-FLI1 are sufficient to downregulate EWS-FLI1 protein. Western blot of A673 cells with 
shEF constructs #1 and #2 after incubation with 0.1ng/µl doxycycline for 48h. (C) Inducible EWS-FLI1 
exchange cell lines. Double transduced A673 cells were incubated with 0.1ng/µl doxycycline for 48h. 
Endogenous and exogenous EWS-FLI1 protein levels were analyzed by western blotting using anti-FLI1 
antibody, (D) and mRNA levels were analyzed by quantitative RT-PCR, with n=4 and error bars represent 
95% confidence intervals. 
 
 
Figure 6: Differential regulation of target gene expression by EWS-FLI1 protein levels. (A) 
Analysis of microarray expression data of A673 exchange cell lines reveals three subgroups of target gene 
regulation. Pie chart distribution for EWS-FLI1 activated (upper) and repressed (lower) target genes and 
their differential modulation of stabilized over wild type EWS-FLI1. (B-C) Heat map of activated-rescued 
(B) and repressed-rescued (C) target gene signature. The comparison of stabilized over wild type EWS-
FLI1 target genes resembled in three distinct groups. (D-E) Validation of selected activated (D) or 
repressed (E) target genes by quantitative RT-PCR based on RNA extracted from shEF#2 exchange cell 
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AFLI1 K252 peptide spectraC
ITMS + c NSI d Full ms2 884.95@cid35.00 [230.00-2000.00]
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FLI1 K172 peptide spectra
ITMS + c NSI d Full ms2 583.78@cid35.00 [150.00-1180.00]



























































































Supplementary S1 - Mass spectrometry
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6ITMS + c NSI d Full ms2 1179.94@cid35.00 [310.00-2000.00]













































































































EWS-FLI1 K298 peptide spectra
Sample Lysine  Residue Peptide sequence Predicted  Observed  
  residue  number   mass mass 
EWS-FLI1 K298 287-318 SPPLGGAQTISKNTEQRPQPDPYQILGPTSSR 3533.79 3533.78 
EWS-FLI1 R386N  K380 372-383 SKPNMNYDKLSR 1565.76 1565.75 
      
FLI1 wild type K172 170-177 MNKEDFLR 1165.56 1165.55 







   S-3 
Mass spectrometry (MS) – extended description for sample preparation and analysis 
 
Purification and sample preparation for MS. 
Proteins were purified from HEK293T cells under denaturing conditions and separated by gel electrophoresis as 
described. The gel was stained with coomassie (Instant blue, Expedeon, Harston, UK) for 20min followed by 
washing with water for each 30min twice. Bands corresponding to the molecular weight of ubiquitinated EWS-
FLI1 were excised from the gel and dried by speed vacuum for 10min. Digestion was performed with 50ng 
Trypsin (Promega, V511C) overnight at 37°C and stopped by addition of 0.2µl formic acid (FA). Peptides were 
extracted from the gel by adding twice 50% acetonitrile (ACN)- 5% trifluoroacetic acid (TFA). 
After drying by speed vacuum for 1h, peptides were cleaned with ZIP-TIP C18 tips (ThermoFisher Scientific AG) 
by resuspending in 3% ACN- 0.1% TFA and eluted with 60% ACN- 0.1% TFA twice. Final resuspension was in 
3% ACN- 0.2% FA with 10mM citric acid before injection into an LTQ-OrbitrapVelos mass spectrometer 
(ThermoFisher Scientific AG) coupled to an EksigentNanoLC-Ultra 1D plus (Eksigent Technologies, Dublin, CA, 
USA). Solvent composition at the two channels was 0.1% FA for channel A and 0.1% FA, 99.9% ACN for channel 
B. Peptides were loaded on a self-made frit column (75μm × 150mm) packed with reverse phase C18 material 
(ReproSil-Pur 120 C18-AQ, 1.9µm, Dr. Maisch GmbH, Ammerbuch, Germany) and eluted at a flow rate of 250nl 
per min by a gradient from 3 to 30% of B in 56min. Full-scan MS spectra (300−1700 m/z) were acquired in profile 
mode at a resolution of 30’000 at 400 m/z, an accumulation gain control (AGC) of 1x106 and a maximum injection 
time of 200ms. Collision induced dissociation (CID) MS/MS spectra were recorded in data dependent manner in 
the ion trap from the twenty most intense signals above a threshold of 1000, using a normalized collision energy 
of 35% and an activation time of 10ms. The AGC value for MS/MS analysis was set to 1x104 (ion trap detection, 
100ms injection time) and the isolation width was set to 2amu. Charge state screening was enabled and singly 
charge states were rejected. Precursor masses already selected for MS/MS were excluded for further selection 
for 45s and the exclusion window was set to 10ppm. The size of the exclusion list was set to a maximum of 500 
entries. The samples were acquired using internal lock mass calibration on m/z 429.088735 and 445.120025. 
 
Data analysis.  
The raw-files from the mass spectrometer were converted into Mascot generic files (mgf) with Mascot Distiller 
software 2.4.3.3 (Matrix Science Ltd.,London, UK). The peak lists were searched using Mascot Server 2.3.02 
against the forward UniProtKB/Swiss-Prot database for human, concatenated to a reversed decoyed FASTA 
database consisting of a total of 135,183 proteins with accessions in Gene Ontology compatible format and 260 
common protein contaminants (NCBI taxonomy ID 9606, release date 2012-04-12). The protein sequence of 
EWS-FLI1 (B1PRL2_HUMAN) was included in the database. 
The parameters for precursor tolerance and fragment ion tolerance were set to ± 5ppm and ± 0.8Da, respectively. 
Gly-Gly and oxidation (M) were set as variable modifications. Enzyme specificity was set to trypsin, allowing up to 
1 missed cleavage. Peptides having an expectation value higher of 0.05 and/or a Mascot score lower of 20 were 
excluded. Only peptides with internal lysine modified by glycine-glycine were considered. For the localization of 
glycine-glycine modification, the results of Mascot Site Analysis were used. All the spectra of ubiquitinated 
peptides were manually validated. 
Expression data analysis






2. paired 24h and 48h
EF over shEF:
>1.5-fold up
(rescued, activated target genes)
>1.5-fold down
(rescued, repressed target genes)
3. paired 24h and 48h
K380R / wt EF:
>1.5-fold
= EF protein dependent 
<0.75-fold
= EF turnover dependent 
<0.75-fold
= EF protein dependent 
>1.5-fold
= EF turnover dependent 
between 0.75-fold  and 1.5-fold
= EF protein saturated target gene modulation
Supplementary S2 - microarray expression analysis
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S2 supplementary table: List of activated target ge nes which expression is either EWS-FLI1 protein sen sitive or turnover sensitive
EWS-FLI1 protein level sensitive
Fold change
Identifier Gene Symbol mRNA Accession mRna - Description  (K380R / wild type EF) Citation
1 17121292 SORD ENST00000267814 ensembl_havana_transcript:known chromosome:GRCh38:15:45023104:45077185:1 gen 1,99 protein-coding
2 16748814 LOC102724196 XR_432795 PREDICTED: Homo sapiens uncharacterized LOC102724196 (LOC102724196), ncRNA 2,23 non-coding RNA
3 16802461 LINC00277 NR_026949 Homo sapiens long intergenic non-protein coding RNA 277 (LINC00277), long non-codin 2,06 non-coding RNA Howarth et al. 2012
17121206 LINC00277 NR_026949 Homo sapiens long intergenic non-protein coding RNA 277 (LINC00277), long non-codin 1,79 non-coding RNA
4 16784564 --- NONHSAT037063 Non-coding transcript identified by NONCODE: Linc 1,86 non-coding RNA
5 16769250 IGF1 NM_000618 Homo sapiens insulin-like growth factor 1 (somatomedin C) (IGF1), transcript variant 4, 2,81 protein-coding Cironi et al. 2008
6 16712944 KIAA1462 NM_020848 Homo sapiens KIAA1462 (KIAA1462), mRNA. 1,66 protein-coding
7 16967875 PARM1 NM_015393 Homo sapiens prostate androgen-regulated mucin-like protein 1 (PARM1), mRNA. 1,56 protein-coding
8 16754269 TRHDE NM_013381 Homo sapiens thyrotropin-releasing hormone degrading enzyme (TRHDE), mRNA. 1,52 protein-coding
9 16833184 LOC102724731 XR_424812 PREDICTED: Homo sapiens uncharacterized LOC102724731 (LOC102724731), transcr 1,94 non-coding RNA
10 17126082 --- --- non-annotated 1,57 unknown
11 17126124 --- --- non-annotated 1,57 unkonwn
12 16690739 KCNA2 NM_001204269 Homo sapiens potassium voltage-gated channel, shaker-related subfamily, member 2 (K 1,72 protein-coding
13 16939479 ENTPD3 NM_001248 Homo sapiens ectonucleoside triphosphate diphosphohydrolase 3 (ENTPD3), transcript 1,83 protein-coding
14 16698489 LEMD1 NM_001001552 Homo sapiens LEM domain containing 1 (LEMD1), transcript variant 3, mRNA. 3,96 protein-coding
15 16837348 MAP2K6 NM_002758 Homo sapiens mitogen-activa torp40,2.ANRm ,)6K2PAM( 6 esanik esanik nietorp det ein-coding
EWS-FLI1 turnover sensitive
Fold change
Identifier Gene Symbol mRNA Accession mRna - Description  (K380R / wild type EF)
1 16972108 APELA ENST00000507152 havana:novel chromosome:GRCh38:4:164877004:164897523:1 gene:ENSG000002483 0,56 protein-coding
2 16949537 TP63 NM_001114978 Homo sapiens tumor protein nietorp75,0.ANRm ,2 tnairav tpircsnart ,)36PT( 36p -coding
3 16894044 LINC01249 NR_034134 Homo sapiens long intergenic non-protein coding RNA 1249 (LINC01249), long non-cod 0,56 non-coding RNA
4 16679349 KMO NM_003679 Homo sapiens kynurenine 3-monooxygenase (kynurenine 3-hydroxylase) (KMO), mRNA 0,58 protein-coding
5 16777544 LINC00463 NR_120428 Homo sapiens long intergenic non-protein coding RNA 463 (LINC00463), long non-codin 0,57 non-coding RNA
6 17010005 BAI3 NM_001704 Homo sapiens brain-specific a oc-nietorp54,0.ANRm ,)3IAB( 3 rotibihni sisenegoign ding
7 16909277 SPHKAP NM_001142644 Homo sapiens SPHK1 interactor, AKAP domain containing (SPHKAP), transcript variant 0,38 protein-coding
8 16947022 RP11-454C18.1 OTTHUMT000003578cdna:all chromosome:VEGA56:3:151637174:151657966:1 Gene:OTTHUMG000001598 0,51 unknown
9 16670185 LOC284561 AK023809 Homo sapiens cDNA FLJ13747 fis, clone PLACE3000276. 0,37 non-coding RNA
10 16674965 --- NONHSAT008377 Non-coding transcript identified by NONCODE: Linc 0,53 non-coding RNA
11 16896049 ALK NM_004304 Homo sapiens anaplastic lymph ietorp26,0.ANRm ,)KLA( esanik enisoryt rotpecer amo n-coding
12 16816962 SCNN1G NM_001039 Homo sapiens sodium channel, non-voltage-gated 1, gamma subunit (SCNN1G), mRNA 0,64 protein-coding
13 16851801 RNF125 NM_017831 Homo sapiens ring finger protein 125, E3 ubiquitin protein ligase (RNF125), mRNA. 0,50 protein-coding
14 17120752 C12orf55 ENST00000524981 havana:putative chromosome:GRCh38:12:96489587:96875555:1 gene:ENSG00000188 0,42 protein-coding
15 16780133 SLITRK6 NM_032229 Homo sapiens SLIT and NTR nietorp63,0.ANRm ,)6KRTILS( 6 rebmem ,ylimaf ekil-K -coding
16 16982264 MTNR1A NM_005958 Homo sapiens melatonin receptor 1A (MTNR1A), mRNA. 0,43 protein-coding
17 17004536 LOC101928047 XR_249939 PREDICTED: Homo sapiens uncharacterized LOC101928047 (LOC101928047), ncRNA 0,52 non-coding RNA
18 17016390 HIST1H2BG NM_003518 Homo sapiens histone cluster 1, H2bg (HIST1H2BG), mRNA. 0,65 protein-coding
19 17125422 CD99P1 NR_033381 Homo sapiens CD99 molecule pseudogene 1 (CD99P1), transcript variant 2, non-coding 0,48 non-coding RNA
20 16975642 GABRA4 NM_000809 Homo sapiens gamma-aminobutyric acid (GABA) A receptor, alpha 4 (GABRA4), transc 0,34 protein-coding
21 17063507 KDM7A NM_030647 Homo sapiens lysine (K)-spe idoc-nietorp35,0.ANRm ,)A7MDK( A7 esalyhtemed cific ng
22 16733038 RNU6-321P ENST00000410912 ncrna:known chromosome:GRCh38:11:125277552:125277657:1 gene:ENSG000002228 0,20 non-coding RNA
23 16666055 CTH ENST00000346806 ensembl_havana_transcript:known chromosome:GRCh38:1:70411383:70439204:1 gene 0,61 protein-coding
24 16685593 --- NONHSAT002513 Non-coding transcript identified by NONCODE: Linc 0,27 non-coding RNA
25 17005072 RNU6-522P ENST00000364497 ncrna:known chromosome:GRCh38:6:15314920:15315026:1 gene:ENSG00000201367 0,39 non-coding RNA
26 16669278 FAM46C NM_017709 Homo sapiens family with sequence similarity 46, member C (FAM46C), mRNA. 0,62 protein-coding
27 17115913 --- NONHSAT139285 Non-coding transcript identified by NONCODE: Linc 0,64 non-coding RNA
28 16669105 MAB21L3 NM_152367 Homo sapiens mab-21-like gnidoc-nietorp54,0.ANRm ,)3L12BAM( )snagele .C( 3
29 17013657 ULBP1 NM_025218 Homo sapiens UL16 binding protein 1 (ULBP1), mRNA. 0,31 protein-coding
S-5
S2 supplementary table: List of repressed target ge nes which repression is either EWS-FLI1 protein sen sitive or turnover sensitive
EWS-FLI1 protein level sensitive
Fold change
itpircseD - anRmnoisseccA ANRmlobmyS eneGreifitnedI )FE epyt dliw / R083K( no
1 17077502 TOX NM_014729 Homo sapiens thymocyte selection-associated high mobility group box (TOX), mRNA. 0,60 protein-coding
2 16888270 ITGA4 NM_000885 Homo sapiens integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor) (ITG 0,58 protein-coding
3 16778241 POSTN NM_001135934 Homo sapiens periostin, osteoblast specific factor (POSTN), transcript variant 2, mRNA 0,52 protein-coding
4 16811085 ITGA11 NM_001004439 Homo sapiens integrin, alpha 11 (ITGA11), mRNA. 0,63 protein-coding
EWS-FLI1 turnover sensitive
Fold change
itpircseD - anRmnoisseccA ANRmlobmyS eneGreifitnedI )FE epyt dliw / R083K( no
1 16878731 EHD3 NM_014600 Homo sapiens EH-domain containing 3 (EHD3), mRNA. 1,69 protein-coding
2 16821377 CDH13 NM_001220488 Homo sapiens cadherin 13 doc-nietorp55,1.ANRm ,2 tnairav tpircsnart ,)31HDC( ing
3 16671457 IL6R NM_000565 Homo sapiens interleukin 6 re etorp65,1.ANRm ,1 tnairav tpircsnart ,)R6LI( rotpec in-coding
4 17117110 CD24 BC064619 Homo sapiens CD24 molecule, mRNA (cDNA clone MGC:75043 IMAGE:5591617), com 10,97 protein-coding
5 17020258 BMP5 NM_021073 Homo sapiens bone morphogenet gnidoc-nietorp10,2.ANRm ,)5PMB( 5 nietorp ci
6 16805287 MIR3175 NR_036136 Homo sapiens microRNA 3175 (MIR3175), microRNA. 1,96 non-coding RNA
17118970 MIR3175 NR_036136 Homo sapiens microRNA 3175 (MIR3175), microRNA. 1,96 non-coding RNA
7 16979613 --- NONHSAT098206 Non-coding transcript identified by NONCODE: Linc 1,67 non-coding RNA
8 17044046 RPL23P8 NR_026673 Homo sapiens ribosomal protein L23 pseudogene 8 (RPL23P8), non-coding RNA. 1,65 non-coding RNA
S-6
Supplementary table ST1: List of plasmids and primers  used for cloning and mutagensis + list of assay on  demand for qRT-PCR
General plasmids:
pCMV-3xflag Sigma Aldrich
etutitsnI hcraeseR recnaC s'nerdlihC ,ravoK .H1ILF-SWE , Vienna, Austria
EWSR1 H. Gehring, University of Zurich, Switzerland
FLI1 J. Ghysdael, Institute Curie, France   (Bailly et al. 1994 MolCellBiol)
Primer name Primer sequence   5'-3' Cloning strategy
1ILF-SWECCATGACATTAGGCACCTGCGCGCCGGCGTTCGAACAGWF SWE-galfx3-VMCp , EWS into pCMV-3xflag
LFGAAGACTGACTCAGTATTCTTCCCAAACGCCGGCGTTCGAACAGWF 1ILFgalfx3-VMCp I1 into pCMV-3xflag
TGTGAATCCGTCGATGATGATCACTCGCCGGCGCTTAAGTAGSR 1ILF-galfx3-VMCp GA EWS-FLI1, FLI1 into pCMV-3xflag
ni SWEGTCTCTAGCCGGGATGATCACTCGCCGGCGCTTAAGTAGSR SWE-galfx3-VMCp to pCMV-3xflag





MSCV-CMV-DsRed-IRES-d24EGFP Addgene  #41944
Primer name Primer sequence   5'-3' Cloning strategy
RIG  FW TAG AGC TAG CGA ATT CAT GGC CTC CTC CGA GGA C #41941/2/3/4 into pR-EF1
RIG RS ATT TAA ATT CGA ATT CTT GGC CAG ATC TGA GTC C #41941 into pR-EF1
24914#GAC GAT CCT AGT TAC ACA TCC TTA AGC TTA AAT TTASR PFGE 4/1d /3 into pR-EF1
4#GT ACC TGC TCG ACA TGT TCA TTC TTA AGC TTA AAT TTASR PFGE 42d 1944 into pR-EF1
WECC ATG ACA TTA GGC ACC TGC GTA AAG CTT AAA GAC CGG TCTWF FE GIR S/FLI1, EWS in pR-EF1-RIG
TGT GAA TCC GTC GAT GAT GAT CAT TAA GCT TAA ATT TAG CCTSR FE GIR  G EWS/FLI1, FLI1 in pR-EF1-RIG
C GTC TCT AGC CGG GAT GAT CAT TAA GCT TAA ATT TAG CCTSR SWE GIR EWS in pR-EF1-RIG
FC GGA GGA ATT ATC AGG GCA GTA AAG CTT AAA GAC CGG TCTSR ILF GIR LI1 in pR-EF1-RIG
Exchange cell lines - plasmids:
'3 AATATTCGAAGGGTGGAGATA '5 ecneuqes tegraT1#FEhs atcelleC
TAGAGTTTGGTCTTGTACTGC '5 ecneuqes tegraT2#FEhs atcelleC  3'
pINDUCER21 (ORF-EG) Addgene #46948
Primer name Primer sequence   5'-3' Cloning strategy
3C AGT ACC AGA AAC ATC AGG TAT GAT CAA GCC CCG GCGWF FE fx3 dnIp xflag-EWS-FLI1, 3xflag into pInducer21
CC GTC GAT GAT GAT CAT CAA GCT TAT GGG TAT GCTSR FE fx3 dnIp T AAG 3xflag-EWS-FLI1 into pInducer21
C GAA CGC CGG CGT ATC ATC AAG CTT ATG GGT ATGSR galfx3 dnIp TT GTC 3xflag into pInducer21
Primer for site directed mutagenesis
Primer name Primer sequence   5'-3' Mutagenesis
ILF-SWECCC GGC AAC GAG ACA TAA GGA TGA CTA GCA AAC ACG GGGWF R892K FE 1 and FLI1 in K298/252>R
T GTT TGC TAG TCA TCC TTA TGT CTC GTT GCC GGGSR R892K FE GC CCC EWS-FLI1 and FLI1 in K298/252>R
-SWECTC CCG GGC CGA GTC GGA CAG CAT TAA GTA CAA CCC GAAWF R083K FE FLI1 and FLI1 in K380/334>R
GGG TTG TAC TTA ATG CTG TCC GAC TCG GCC CGG GAGSR R083K FE  CTT EWS-FLI1 and FLI1 in K380/334>R
1ILFC AGG AGG GAC AAG TAA AAT GTG TCA AGG AAC GGT AGGWF R271K 1ILF  in K172>R
 CCG TTC CTT GAC ACA TTT TAC TTG TCC CTC CTGSR 271K 1ILF ATC C FLI1 in K172>R
N>683R ni 1ILF-SWEGTATCATTATTAACTCCCGGGCCGAGTCWF N683R FE
N>683R ni 1ILF-SWEGACTCGGCCCGGGAGTTAATAATGATACSR N683R FE
List of commercially available  assay on demand for  qRT-PCR
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